Cargando…

PCSK9 inhibitors: A new era of lipid lowering therapy

Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhary, Rahul, Garg, Jalaj, Shah, Neeraj, Sumner, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329749/ https://www.ncbi.nlm.nih.gov/pubmed/28289523 http://dx.doi.org/10.4330/wjc.v9.i2.76

Ejemplares similares

PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy
por: Hajar, Rachel
Publicado: (2019)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
por: Yamashita, Satoshi, et al.
Publicado: (2023)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
por: Khoshnejad, Makan, et al.
Publicado: (2019)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

PCSK9 inhibitors: Add-on therapy to reduce stroke risk
por: Earl, Grace
Publicado: (2019)

Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
por: Farrah, Tariq E., et al.
Publicado: (2019)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
por: Seijas-Amigo, Jose, et al.
Publicado: (2022)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis
por: Chaudhary, Rahul, et al.
Publicado: (2017)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
por: Jaworski, Krzysztof, et al.
Publicado: (2017)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
por: Palee, Siripong, et al.
Publicado: (2019)

Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
por: Zhang, Yan, et al.
Publicado: (2014)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
por: Caso, Valentina Maria, et al.
Publicado: (2022)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qri4pvpusrkftaq96tgfhhv74v